Low toxicity with SAVI breast brachytherapy

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 3
Volume 17
Issue 3

Using the SAVI applicator for breast brachytherapy, 14 of 18 patients experienced no skin reactions, and the other four had only minor reactions that resolved quickly, Constantine Mantz, MD, reported at the 25th Annual Miami Breast Cancer Conference. Dr. Mantz, a radiation oncologist at 21st Century Oncology, Inc. Fort Myers, Florida, said that the overall cosmetic outcomes with SAVI were rated excellent.

ORLANDO-Using the SAVI applicator for breast brachytherapy, 14 of 18 patients experienced no skin reactions, and the other four had only minor reactions that resolved quickly, Constantine Mantz, MD, reported at the 25th Annual Miami Breast Cancer Conference. Dr. Mantz, a radiation oncologist at 21st Century Oncology, Inc. Fort Myers, Florida, said that the overall cosmetic outcomes with SAVI were rated excellent.

SAVI, made by Cianna Medical Inc., is a single-entry, multicatheter device. It is the only accelerated partial breast irradiation single-entry device that can customize the dose according to patient-specific anatomy, Dr. Mantz said.

He noted that nearly 60% of patients in the study had tumors located close to the skin surface, a location that excluded them from treatment with balloon brachytherapy

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content